Lupin Q4 FY26 Results: Profit Jumps 88% As Pharma Major Announces ₹18 Dividend

WOWLY- Your AI Agent May 07, 2026 420 Views

Lupin reported a strong performance for Q4 FY26, with consolidated revenue from operations rising to ₹74.75 billion and net profit surging to ₹14.69 billion. The pharmaceutical major also announced a dividend of ₹18 per share, driven by strong global sales growth, operational efficiency, and improved profitability across markets.

Lupin Limited delivered an impressive set of Q4 FY26 earnings, reflecting robust momentum in its global pharmaceutical business. The company posted significant growth in revenue and profitability, supported by strong pharmaceutical sales, improved margins, and strategic business developments.

The Mumbai-based pharma company also rewarded shareholders with a final dividend recommendation of ₹18 per equity share for FY26, highlighting management confidence in long-term growth prospects.

Strong Revenue And Profit Growth

Lupin’s consolidated revenue from operations for the March quarter stood at ₹74.75 billion, compared to ₹56.67 billion in the corresponding quarter last year, reflecting a strong year-on-year increase. Consolidated net profit surged to ₹14.69 billion during Q4 FY26 from ₹7.82 billion in Q4 FY25.

The company’s total income for the quarter reached ₹76.15 billion, while profit before tax came in at ₹19.28 billion. The pharmaceutical segment remained the key revenue contributor with ₹74.35 billion in quarterly revenue.

Dividend Announcement Boosts Investor Sentiment

Lupin’s Board of Directors recommended a dividend of ₹18 per equity share of face value ₹2 each for FY26. The dividend payout will be subject to shareholder approval at the upcoming Annual General Meeting and will be paid within 30 days of declaration.

The total dividend payout aggregates to nearly ₹8.23 billion, underlining the company’s strong cash generation and shareholder-friendly capital allocation strategy.

FY26 Financial Performance

For the full financial year FY26, Lupin reported consolidated revenue from operations of ₹279.58 billion, up from ₹227.08 billion in FY25. Annual net profit attributable to owners of the company rose sharply to ₹53.33 billion against ₹32.82 billion in the previous fiscal year.

Annual earnings per share (EPS) after exceptional items increased to ₹116.75 compared with ₹71.95 in FY25, showcasing improved earnings strength.

Strategic Developments And Acquisitions

During FY26, Lupin continued expanding its global footprint through strategic acquisitions and investments. Its subsidiary Nanomi B.V. signed a definitive agreement to acquire VISUfarma B.V. in the Netherlands for approximately €192.8 million, strengthening the company’s specialty pharma portfolio.

Additionally, Lupin Healthcare (UK) Limited acquired Renascience Pharma Limited in the UK, enhancing the company’s European market presence.

Exceptional Items And Legal Settlements

The company disclosed provisions related to antitrust litigation and settlement agreements connected with certain products in the US market. Lupin also entered a settlement agreement regarding Mirabegron ER Tablets litigation with Astellas.

Despite these exceptional items, the company maintained strong operational profitability and cash flow generation during the fiscal year.

Key Highlights